N/A N=131 Clinical Evaluation of Approved and Investigational Contact Lenses Using New UV Additive
Visual Acuity
Primary: Eyestrain Related to Glare — 44.64; 45.37; 46.40; 44.59 Units on a Scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=41 A Study of LY3053102 in Healthy Participants
Healthy Volunteers
Primary: Number of Participants With One or More Adverse Events (AEs) or Any Serious AEs — 5; 6; 4; 4 participants
Phase 3 N=173 A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin
Chronic Renal Failure Requiring Hemodialysis
Primary: Percentage of Participants With Treatment Emergent Adverse Events (AEs): Week 1 — 17.4 Percentage of participants
Phase 3 N=112 Oleogel-S10 in Wound Healing of Split-Thickness Skin Graft Donor Sites (BSG-12)
Wounds
Primary: Intra-individual Difference in Time to Wound Closure — -0.8 days — p==0.0232
Phase 2 N=56 Psychopharmacology of Psilocybin in Cancer Patients
Depressive Symptoms · Anxiety · Cancer
Primary: GRID-HAM-D-17 -- Structured Interview Guide for the Hamilton Depression Scale. — 22.32; 14.8; 6.5; 6.95 units on a scale
Phase 2 N=41 Study With IMC-A12 (Cixutumumab) in Patients Who Have Not Previously Been Treated With Chemotherapy With Metastatic Prostate Cancer
Adenocarcinoma of the Prostate
Primary: Composite Time to Disease Progression (cTTP) for Participants Treated With Cixutumumab — 4.9; 3.2 months
Phase 2 N=53 Safety and Efficacy Study of Ipilimumab 3 mg/kg Versus Ipilimumab 10 mg/kg in Subjects With Metastatic Castration Resistant Prostate Cancer Who Are Chemotherapy Naive
Prostate Cancer
Primary: Radiographic Progression-free Survival (rPFS) — 4; 3 Participants
N/A N=57 Dry Eye Symptom Relief Assessment With Use of TrueTear in a Controlled Adverse Environment
Dry Eye · Dry Eye Syndromes
Primary: Eye Dryness Score — 48 Score on Scale — p=0.0001
Phase 1 N=56 A Study of LY3016859 in Healthy Volunteers
Healthy Volunteers
Primary: Number of Participants With One or More Drug-Related Treatment-Emergent Adverse Events (TEAEs) or Any Serious AEs (SAE) — 2; 0; 2; 3 participants
Phase 2 N=13 Safety and Efficacy of a Combination Product for the Prevention of Veisalgia
Veisalgia
Primary: Efficacy of Side Effect Prevention Using the Acute Hangover Scale — 6.7; 4.7; 7.8; 6.8 score on a scale
Phase 3 N=414 A Phase 3, Long-Term Safety Study of Intravenous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin
Chronic Renal Failure Requiring Hemodialysis
Primary: Percentage of Participants With Treatment Emergent Adverse Events (AEs): Week 1 — 13.0 Percentage of participants
Phase 2 N=270 A Study of LY2409021 on Blood Pressure and Pulse Rate in Participants With Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Primary: Change From Baseline to 6 Weeks in Mean 24-Hour Systolic Blood Pressure — 2.79; 0.53 mmHg — p=<.001
Phase 4 N=43 Outcomes of Neuraxial Anesthetic Technique on the Trial of Labor After Cesarean (TOLAC)
Labor Pain · Complications; Cesarean Section · Pregnancy
Primary: Number of Participants With Vaginal Birth After Cesarean (VBAC) — 12; 22 Participants
Phase 3 N=40 Gabapentin for Abstinence Initiation in Alcohol Dependence
Alcohol Dependence
Primary: Percent of Heavy Drinking Days Per Week — 22.5; 53.9 percent of heavy drinking days
Phase 3 N=162 A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis Naive to Systemic Treatment
Plaque Psoriasis
Primary: Percentage of Participants With a ≥75% Improvement in Psoriasis Area and Severity Index (PASI 75) at Week 24 — 90.7; 22.2; 70.4 Percentage of Participants — p=<.0001